GSK Pharmaceuticals Issues Corrigendum to Postal Ballot Notice Dated Aug 3, 2026
GlaxoSmithKline Pharmaceuticals Limited issued a corrigendum to its August 3, 2026 postal ballot notice. The correction clarifies a typographical error in Mr. Akshikar's basic salary, which should be ₹24,00,000 per month. The corrigendum was emailed to members on September 1, 2026, and will be published in a newspaper.
The announcement concerns a minor typographical correction in a previously issued notice and is unlikely to have any significant impact on the company's business, financials, or stock performance.
The announcement is a correction of a minor typographical error and does not materially affect the company's operations or financial standing. It is a routine administrative update.
GlaxoSmithKline Pharmaceuticals Limited has issued a corrigendum to its postal ballot notice dated August 3, 2026. The corrigendum, sent via email to members on September 1, 2026, addresses a typographical error in the explanatory statement concerning the basic salary of Mr. Akshikar. The correct basic salary should be stated as ₹24,00,000 per month, rather than the previously mentioned ₹24,00,0000 per month.
This corrigendum is an integral part of the original notice and explanatory statement, which were circulated to members on August 13, 2026. The company will also publish a notice in the newspaper regarding this correction. All other details of the original notice remain unchanged. The corrigendum has been uploaded to the company's investor relations website.
A plain-language summary of a public exchange filing by GlaxoSmithKline Pharmaceuticals Limited. Read the original for the full detail.